Study Links Stopping GLP-1 Diabetes Drugs to Heart Risks
· Business · ABC News (AU), The Independent
A study of 80,000 Italian patients with type 2 diabetes suggests that stopping GLP-1 receptor agonists, such as Ozempic, may be associated with an increased risk of heart attack, stroke, or death. Published in The Lancet Regional Health — Europe, the research found that 4% of those who stopped the medication experienced adverse cardiovascular events, compared to 2% of those who continued treatment. Lead author Antonio Ceriello noted that the risk was higher among patients with obesity. However, experts urge caution as the study cannot prove causation and did not investigate the specific reasons why patients ceased their medication.
Why it matters
Patients with type 2 diabetes are advised to consult their doctors before stopping GLP-1 medications, as the findings suggest potential cardiovascular risks associated with treatment cessation.
Read the original report — ABC News (AU)
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.